Country Club Bank cut its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 1.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 87,562 shares of the company’s stock after selling 1,157 shares during the period. Country Club Bank’s holdings in Merck & Co., Inc. were worth $6,926,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC increased its holdings in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares in the last quarter. First Citizens Bank & Trust Co. boosted its holdings in shares of Merck & Co., Inc. by 67.0% during the 1st quarter. First Citizens Bank & Trust Co. now owns 83,216 shares of the company’s stock valued at $7,469,000 after acquiring an additional 33,378 shares during the last quarter. Werlinich Asset Management LLC boosted its holdings in shares of Merck & Co., Inc. by 9.9% during the 1st quarter. Werlinich Asset Management LLC now owns 28,120 shares of the company’s stock valued at $2,524,000 after acquiring an additional 2,530 shares during the last quarter. Foundation Resource Management Inc. grew its stake in shares of Merck & Co., Inc. by 46.8% in the first quarter. Foundation Resource Management Inc. now owns 186,197 shares of the company’s stock worth $16,713,000 after acquiring an additional 59,369 shares during the period. Finally, Baldwin Wealth Partners LLC MA raised its holdings in shares of Merck & Co., Inc. by 1.9% during the first quarter. Baldwin Wealth Partners LLC MA now owns 200,550 shares of the company’s stock valued at $18,001,000 after purchasing an additional 3,794 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts recently issued reports on MRK shares. Wells Fargo & Company dropped their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. Morgan Stanley cut their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $104.31.
Merck & Co., Inc. Stock Performance
NYSE:MRK opened at $88.83 on Tuesday. The stock has a 50-day simple moving average of $82.96 and a two-hundred day simple moving average of $81.48. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $111.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The firm has a market capitalization of $221.88 billion, a PE ratio of 13.69, a P/E/G ratio of 0.92 and a beta of 0.37.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current year.
Merck & Co., Inc. Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be given a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 49.92%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- How to Use Stock Screeners to Find Stocks
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- Business Services Stocks Investing
- 3 Exceptional Stocks to Build Long-Term Wealth
- Are Penny Stocks a Good Fit for Your Portfolio?
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.